PapersFlow Research Brief
Neurological Disorders and Treatments
Research Guide
What is Neurological Disorders and Treatments?
Neurological Disorders and Treatments is the investigation of neuroprotective agents such as Citicoline and Cerebrolysin in contexts including oxidative stress, ischemic stroke, brain injury, glaucoma, and neurodegenerative diseases like Alzheimer's, focusing on their mechanisms of action, effects on mitochondrial dysfunction, neuroprotection, and potential for neuroregeneration.
This field encompasses 88,785 papers on neurological disorders and their treatments. Research targets neuroprotective agents like Citicoline and Cerebrolysin for conditions such as ischemic stroke, glaucoma, and Alzheimer's disease. Growth rate over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Citicoline in Ischemic Stroke
This sub-topic examines the neuroprotective effects of citicoline in acute ischemic stroke, including its impact on neuronal repair and functional outcomes in clinical trials. Researchers study its mechanisms in reducing infarct size and improving recovery post-stroke.
Cerebrolysin in Neurodegenerative Diseases
This sub-topic investigates Cerebrolysin's role in Alzheimer's disease and other neurodegenerative conditions, focusing on neuroregeneration and cognitive improvement. Studies explore its effects on amyloid pathology and synaptic plasticity.
Oxidative Stress in Glaucoma
Researchers analyze oxidative stress mechanisms in retinal ganglion cell death in glaucoma, including antioxidant interventions. This includes mitochondrial dysfunction and neuroprotection strategies for optic nerve preservation.
Neuroprotective Agents in Traumatic Brain Injury
This sub-topic covers the use of agents like Citicoline and Cerebrolysin in traumatic brain injury, targeting oxidative stress and mitochondrial function. Research evaluates their efficacy in reducing secondary injury and promoting recovery.
Mitochondrial Dysfunction in Alzheimer's Disease
Studies focus on mitochondrial impairments contributing to Alzheimer's pathology and the modulatory effects of neuroprotective agents. Researchers investigate bioenergetic failure, ROS production, and therapeutic targeting.
Why It Matters
Antithrombotic therapies prevent death, myocardial infarction, and stroke, as demonstrated in a collaborative overview of randomized trials showing prolonged antiplatelet therapy reduces these events across patient categories (Altman et al., 1994, "COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS"). Classification of ischemic stroke subtypes guides prognosis, outcome, and management in multicenter clinical trials, with the TOAST system categorizing based on etiology (Adams et al., 1993, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment."). Mild cognitive impairment (MCI) represents a transitional state between normal aging and Alzheimer's disease, prompting assessment with validated tools, evaluation of modifiable risk factors, and monitoring of cognitive status (Petersen et al., 2001, "Current Concepts in Mild Cognitive Impairment"; Petersen et al., 2017, "Practice guideline update summary: Mild cognitive impairment [RETIRED]"). The cholinergic hypothesis underpins Alzheimer's treatments, with research linking cholinergic deficits to 50%-60% of dementia cases in those over 65 (Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress").
Reading Guide
Where to Start
"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment." by Adams et al. (1993), as it provides a foundational system for categorizing stroke subtypes essential for understanding treatment trials.
Key Papers Explained
Adams et al. (1993) in "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment." establishes etiology-based stroke classification, which Altman et al. (1994) in "COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS" applies to antiplatelet prevention across categories. Petersen et al. (2001) in "Current Concepts in Mild Cognitive Impairment" defines MCI as a precursor to Alzheimer's, extended by Petersen et al. (2017) in "Practice guideline update summary: Mild cognitive impairment [RETIRED]" with clinical guidelines. Francis et al. (1999) in "The cholinergic hypothesis of Alzheimer's disease: a review of progress" links cholinergic deficits to dementia, building on Montine et al. (2011) guidelines for neuropathologic assessment.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes neuroprotective agents targeting oxidative stress and mitochondrial dysfunction in stroke and Alzheimer's. No recent preprints or news available; frontiers involve mechanisms of Citicoline and Cerebrolysin in neuroregeneration and glaucoma.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Classification of subtype of acute ischemic stroke. Definition... | 1993 | Stroke | 12.0K | ✓ |
| 2 | Current Concepts in Mild Cognitive Impairment | 2001 | Archives of Neurology | 4.7K | ✕ |
| 3 | COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET TH... | 1994 | Oxford University Rese... | 3.3K | ✕ |
| 4 | ON TYROSINE AND TRYPTOPHANE DETERMINATIONS IN PROTEINS | 1927 | Journal of Biological ... | 2.9K | ✓ |
| 5 | National Institute on Aging–Alzheimer’s Association guidelines... | 2011 | Acta Neuropathologica | 2.8K | ✓ |
| 6 | Handbook of Psychopharmacology | 1988 | — | 2.8K | ✕ |
| 7 | Neurovascular regulation in the normal brain and in Alzheimer'... | 2004 | Nature reviews. Neuros... | 2.2K | ✕ |
| 8 | The cholinergic hypothesis of Alzheimer's disease: a review of... | 1999 | Journal of Neurology N... | 2.2K | ✓ |
| 9 | Practice guideline update summary: Mild cognitive impairment [... | 2017 | Neurology | 2.0K | ✓ |
| 10 | Oxidative Stress and Diabetic Vascular Complications | 1996 | Diabetes Care | 1.9K | ✕ |
Frequently Asked Questions
What is the TOAST classification for ischemic stroke?
The TOAST classification categorizes subtypes of acute ischemic stroke based mainly on etiology for use in multicenter clinical trials. It influences prognosis, outcome, and management by measuring therapy responses according to stroke subtype (Adams et al., 1993, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.").
What defines mild cognitive impairment?
Mild cognitive impairment is a transitional state between cognitive changes of normal aging and Alzheimer's disease. It is characterized in the earliest stages of cognitive impairment, prompting assessment with validated tools and monitoring (Petersen et al., 2001, "Current Concepts in Mild Cognitive Impairment").
How does antiplatelet therapy benefit stroke prevention?
Prolonged antiplatelet therapy prevents death, myocardial infarction, and stroke in various patient categories. This is supported by a collaborative overview of randomized trials (Altman et al., 1994, "COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS").
What is the cholinergic hypothesis in Alzheimer's disease?
The cholinergic hypothesis posits deficits in cholinergic systems contribute to Alzheimer's symptoms. It accounts for 50%-60% of dementia cases in persons over 65, guiding research into causes and treatments (Francis et al., 1999, "The cholinergic hypothesis of Alzheimer's disease: a review of progress").
How are Alzheimer's neuropathologic changes assessed?
Guidelines provide a practical approach for neuropathologic assessment of Alzheimer's disease. They standardize evaluation for research and diagnosis (Montine et al., 2011, "National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach").
Open Research Questions
- ? How do neuroprotective agents like Citicoline and Cerebrolysin mitigate mitochondrial dysfunction in ischemic stroke?
- ? What are the precise mechanisms of oxidative stress in glaucoma and retinal ganglion cell loss?
- ? Can subtype-specific treatments based on TOAST classification improve outcomes in acute ischemic stroke beyond current therapies?
- ? What modifiable risk factors most influence progression from mild cognitive impairment to Alzheimer's disease?
- ? How does neurovascular regulation failure contribute to neurodegeneration in Alzheimer's disease?
Recent Trends
The field includes 88,785 works with no specified 5-year growth rate.
Focus persists on stroke subtype classification, MCI progression to Alzheimer's, and antiplatelet therapies, as seen in top-cited papers from 1993-2017.
No recent preprints or news coverage available.
Research Neurological Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurological Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers